<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="30/10/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=8608243" creator="Junko Matsuura">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>8608243</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term sem="Organic_compound_other" id="T1" lex="AM580">AM580</term>, a stable <term sem="Organic_compound_other" id="T2" lex="benzoic_derivative">benzoic derivative</term> of <term sem="Organic_compound_other" id="T3" lex="retinoic_acid">retinoic acid</term>, has powerful and selective <term sem="Other" id="T4" lex="cyto-differentiating_effect">cyto-differentiating effects</term> on <term sem="Cell_cultured" id="T5" lex="acute_promyelocytic_leukemia_cell">acute promyelocytic leukemia cells</term>.</sentence>
<event id="E1">
<type class="Cell_differentiation" />
<theme idref="T5" />
<clue>AM580, a stable benzoic derivative of retinoic acid, has powerful and selective <clueType>cyto-differentiating</clueType> effects <linkTheme>on</linkTheme> acute promyelocytic leukemia cells.</clue>
</event>
<event id="E101">
<type class="Positive_regulation" />
<theme idref="E1" />
<cause idref="T1" />
<clue>AM580, a stable benzoic derivative of retinoic acid, has powerful and selective cyto-differentiating <clueType>effects</clueType> on acute promyelocytic leukemia cells.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term sem="Organic_compound_other" id="T6" lex="all-trans_retinoic_acid">All-trans retinoic acid</term> (<term sem="Organic_compound_other" id="T7" lex="ATRA">ATRA</term>) is successfully used in the <term sem="Other" id="T8" lex="cyto-differentiating_treatment">cyto-differentiating treatment</term> of <term sem="Other" id="T9" lex="acute_promyelocytic_leukemia">acute promyelocytic leukemia</term> (<term sem="Other" id="T10" lex="APL">APL</term>).</sentence>
<event id="E2">
<type class="Artificial_process" />
<theme idref="T10" />
<clue>All-trans retinoic acid (ATRA) is successfully used in the <clueType>cyto-differentiating treatment</clueType> <linkTheme>of</linkTheme> acute promyelocytic leukemia (APL).</clue>
</event>
<sentence id="S3">Paradoxically, <term sem="Cell_cultured" id="T11" lex="APL_cell">APL cells</term> express <term sem="Protein_molecule" id="T12" lex="PML-RAR">PML-RAR</term>, an aberrant form of the <term sem="Protein_molecule" id="T13" lex="retinoic_acid_receptor_type_alpha"><term sem="Organic_compound_other" id="T14" lex="retinoic_acid">retinoic acid</term> receptor type alpha</term> (<term sem="Protein_molecule" id="T15" lex="RAR_alpha">RAR alpha</term>) derived from the <term sem="Other" id="T16" lex="leukemia-specific_t(15;17)_chromosomal_translocation">leukemia-specific t(15;17) chromosomal translocation</term>.</sentence>
<event id="E4">
<type class="Gene_expression" />
<theme idref="T12" />
<clue>Paradoxically, <clueLoc>APL cells</clueLoc> <clueType>express</clueType> PML-RAR, an aberrant form of the retinoic acid receptor type alpha (RAR alpha) derived from the leukemia-specific t(15;17) chromosomal translocation.</clue>
</event>
<event id="E5">
<type class="Positive_regulation" />
<theme idref="T12" />
<cause idref="T16" />
<clue>Paradoxically, APL cells express PML-RAR, an aberrant form of the retinoic acid receptor type alpha (RAR alpha) <clueType>derived</clueType> <linkCause>from</linkCause> the leukemia-specific t(15;17) chromosomal translocation.</clue>
<comment>NER: T16 MOD</comment>
</event>
<sentence id="S4">We show here that <term sem="Organic_compound_other" id="T17" lex="AM580">AM580</term>, a stable <term sem="Organic_compound_other" id="T18" lex="retinobenzoic_derivative">retinobenzoic derivative</term> originally synthesized as a <term sem="Organic_compound_other" id="T19" lex="RAR_alpha_agonist"><term sem="Protein_molecule" id="T20" lex="RAR_alpha">RAR alpha</term> agonist</term>, is a powerful inducer of <term sem="Other" id="T21" lex="granulocytic_maturation">granulocytic maturation</term> in <term sem="Cell_cultured" id="T22" lex="NB4">NB4</term>, an <term sem="Cell_cultured" id="T23" lex="APL-derived_cell_line"><term sem="Other" id="T24" lex="APL">APL</term>-derived cell line</term>, and in <term sem="Cell_natural" id="T25" lex="freshly_isolated_APL_blast">freshly isolated APL blasts</term>.</sentence>
<event id="E6">
<type class="Cell_differentiation" />
<theme idref="T22" />
<clue>We show here that AM580, a stable retinobenzoic derivative originally synthesized as a RAR alpha agonist, is a powerful inducer of <clueType>granulocytic maturation</clueType> <linkTheme>in</linkTheme> NB4, an <corefTheme>APL-derived cell line</corefTheme>, and in freshly isolated APL blasts.</clue>
</event>
<event id="E7">
<type class="Cell_differentiation" />
<theme idref="T25" />
<clue>We show here that AM580, a stable retinobenzoic derivative originally synthesized as a RAR alpha agonist, is a powerful inducer of <clueType>granulocytic maturation</clueType> <linkTheme>in</linkTheme> NB4, an APL-derived cell line, and in freshly isolated APL blasts.</clue>
</event>
<event id="E8">
<type class="Positive_regulation" />
<theme idref="E6" />
<cause idref="T17" />
<clue>We show here that AM580, a stable retinobenzoic derivative originally synthesized as a RAR alpha agonist, is a powerful <clueType>inducer</clueType> <linkTheme>of</linkTheme> granulocytic maturation in NB4, an APL-derived cell line, and in freshly isolated APL blasts.</clue>
</event>
<event id="E9">
<type class="Positive_regulation" />
<theme idref="E7" />
<cause idref="T17" />
<clue>We show here that AM580, a stable retinobenzoic derivative originally synthesized as a RAR alpha agonist, is a powerful <clueType>inducer</clueType> <linkTheme>of</linkTheme> granulocytic maturation in NB4, an APL-derived cell line, and in freshly isolated APL blasts.</clue>
</event>
<sentence id="S5">After treatment of <term sem="Cell_cultured" id="T26" lex="APL_cell">APL cells</term> with <term sem="Organic_compound_other" id="T27" lex="AM580">AM580</term> either alone or in combination with <term sem="Protein_molecule" id="T28" lex="granulocyte_colony-stimulating_factor">granulocyte colony-stimulating factor</term> (<term sem="Protein_molecule" id="T29" lex="G-CSF">G-CSF</term>), the compound induces <term sem="Other" id="T30" lex="granulocytic_maturation">granulocytic maturation</term>, as assessed by determination of the levels of <cons sem="(AND RNA_molecule RNA_molecule RNA_molecule RNA_molecule)" id="T31" lex="(AND leukocyte_alkaline_phosphatase_mRNA CD11b_mRNA CD33_mRNA G-CSF_receptor_mRNA)"><frag id="F1"><term sem="RNA_molecule" id="A5">leukocyte alkaline phosphatase</term></frag>, <frag id="F2"><term sem="RNA_molecule" id="A6">CD11b</term></frag>, <frag id="F3"><term sem="RNA_molecule" id="A7">CD33</term></frag>, and <frag id="F4"><term sem="RNA_molecule" id="A8">G-CSF receptor</term></frag> <frag id="F5"><term sem="RNA_molecule" id="A9">mRNA</term></frag></cons>, at concentrations that are 10- to 100-fold lower than those of <term sem="Organic_compound_other" id="T32" lex="ATRA">ATRA</term> necessary to produce similar effects.</sentence>
<event id="E10">
<type class="Artificial_process" />
<theme idref="T26" />
<theme idref="T27" />
<clue>After <clueType>treatment</clueType> <linkTheme>of</linkTheme> APL cells <linkTheme>with</linkTheme> AM580 either alone or in combination with granulocyte colony-stimulating factor (G-CSF), the compound induces granulocytic maturation, as assessed by determination of the levels of leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA, at concentrations that are 10- to 100-fold lower than those of ATRA necessary to produce similar effects.</clue>
</event>
<event id="E11">
<type class="Artificial_process" />
<theme idref="T26" />
<theme idref="T27" />
<theme idref="T29" />
<clue>After <clueType>treatment</clueType> <linkTheme>of</linkTheme> APL cells <linkTheme>with</linkTheme> AM580 either alone or <linkTheme>in combination with</linkTheme> granulocyte colony-stimulating factor (G-CSF), the compound induces granulocytic maturation, as assessed by determination of the levels of leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA, at concentrations that are 10- to 100-fold lower than those of ATRA necessary to produce similar effects.</clue>
</event>
<event id="E12">
<type class="Positive_regulation" />
<theme idref="T30" />
<cause idref="E10" />
<clue>After treatment of APL cells with AM580 either alone or in combination with granulocyte colony-stimulating factor (G-CSF), <corefCause>the compound</corefCause> <clueType>induces</clueType> granulocytic maturation, <clueExperiment>as assessed by determination of the levels of leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA</clueExperiment>, at concentrations that are 10- to 100-fold lower than those of ATRA necessary to produce similar effects.</clue>
</event>
<event id="E13">
<type class="Positive_regulation" />
<theme idref="T30" />
<cause idref="E11" />
<clue>After treatment of APL cells with AM580 either alone or in combination with granulocyte colony-stimulating factor (G-CSF), <corefCause>the compound</corefCause> <clueType>induces</clueType> granulocytic maturation, <clueExperiment>as assessed by determination of the levels of leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA</clueExperiment>, at concentrations that are 10- to 100-fold lower than those of ATRA necessary to produce similar effects.</clue>
</event>
<event id="E14">
<type class="Positive_regulation" />
<theme idref="T30" />
<cause idref="T32" />
<clue>After treatment of APL cells with AM580 either alone or in combination with granulocyte colony-stimulating factor (G-CSF), the compound induces granulocytic maturation, as assessed by determination of the levels of leukocyte alkaline phosphatase, CD11b, CD33, and G-CSF receptor mRNA, at concentrations that are 10- to 100-fold lower than those of ATRA necessary to <clueType>produce</clueType> <corefTheme>similar effects</corefTheme>.</clue>
</event>
<sentence id="S6">By contrast, <term sem="Organic_compound_other" id="T33" lex="AM580">AM580</term> is not effective as <term sem="Organic_compound_other" id="T34" lex="ATRA">ATRA</term> in modulating the expression of these <term sem="Protein_family_or_group" id="T35" lex="differentiation_marker">differentiation markers</term> in the <term sem="Cell_cultured" id="T36" lex="HL-60_cell_line">HL-60 cell line</term> and in <term sem="Cell_natural" id="T37" lex="freshly_isolated_granulocyte">freshly isolated granulocytes</term> obtained from the <term sem="Tissue_natural" id="T38" lex="peripheral_blood">peripheral blood</term> of <term sem="Multicellular_organism_natural" id="T39" lex="chronic_myelogenous_leukemia_patient">chronic myelogenous leukemia patients</term> during the stable phase of the disease.</sentence>
<event id="E15">
<type class="Gene_expression" />
<theme idref="A5" />
<clue>By contrast, AM580 is not effective as ATRA in modulating the <clueType>expression</clueType> <linkTheme>of</linkTheme> <corefTheme>these differentiation markers</corefTheme> in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E16">
<type class="Gene_expression" />
<theme idref="A6" />
<clue>By contrast, AM580 is not effective as ATRA in modulating the <clueType>expression</clueType> <linkTheme>of</linkTheme> <corefTheme>these differentiation markers</corefTheme> in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E17">
<type class="Gene_expression" />
<theme idref="A7" />
<clue>By contrast, AM580 is not effective as ATRA in modulating the <clueType>expression</clueType> <linkTheme>of</linkTheme> <corefTheme>these differentiation markers</corefTheme> in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E18">
<type class="Gene_expression" />
<theme idref="A8" />
<clue>By contrast, AM580 is not effective as ATRA in modulating the <clueType>expression</clueType> <linkTheme>of</linkTheme> <corefTheme>these differentiation markers</corefTheme> in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E19">
<type class="Regulation" />
<theme idref="E15" />
<cause idref="T33" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E20">
<type class="Regulation" />
<theme idref="E16" />
<cause idref="T33" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E21">
<type class="Regulation" />
<theme idref="E17" />
<cause idref="T33" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E22">
<type class="Regulation" />
<theme idref="E18" />
<cause idref="T33" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E23">
<type class="Regulation" />
<theme idref="E15" />
<cause idref="T34" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E24">
<type class="Regulation" />
<theme idref="E16" />
<cause idref="T34" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E25">
<type class="Regulation" />
<theme idref="E17" />
<cause idref="T34" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<event id="E26">
<type class="Regulation" />
<theme idref="E18" />
<cause idref="T34" />
<clue>By contrast, AM580 is not effective as ATRA in <clueType>modulating</clueType> the expression of these differentiation markers in the HL-60 cell line and in freshly isolated granulocytes obtained from the peripheral blood of chronic myelogenous leukemia patients during the stable phase of the disease.</clue>
</event>
<sentence id="S7">In <term sem="Cell_cultured" id="T40" lex="NB4_cell">NB4 cells</term>, two other <term sem="Organic_compound_other" id="T41" lex="synthetic_nonselective_RAR_ligand">synthetic nonselective RAR ligands</term> are capable of inducing <term sem="Protein_molecule" id="T42" lex="LAP">LAP</term> as much as <term sem="Organic_compound_other" id="T43" lex="AM580">AM580</term>, whereas <term sem="Organic_compound_other" id="T44" lex="RAR_beta-specific_ligand">RAR beta-</term> or <term sem="Organic_compound_other" id="T45" lex="RAR_gamma-specific_ligand">RAR gamma-<term sem="Organic_compound_other" id="A10">specific ligands</term></term> are totally ineffective.</sentence>
<event id="E27">
<type class="Positive_regulation" />
<theme idref="T42" />
<cause idref="T41" />
<clue><clueLoc>In NB4 cells</clueLoc>, two other synthetic nonselective RAR ligands are capable of <clueType>inducing</clueType> LAP as much as AM580, whereas RAR beta- or RAR gamma-specific ligands are totally ineffective.</clue>
</event>
<event id="E28">
<type class="Positive_regulation" />
<theme idref="T42" />
<cause idref="T43" />
<clue><clueLoc>In NB4 cells</clueLoc>, two other synthetic nonselective RAR ligands are capable of <clueType>inducing</clueType> LAP as much as AM580, whereas RAR beta- or RAR gamma-specific ligands are totally ineffective.</clue>
</event>
<event assertion="non-exist" id="E29">
<type class="Positive_regulation" />
<theme idref="T42" />
<cause idref1="A10" idref="T44" />
<clue><clueLoc>In NB4 cells</clueLoc>, two other synthetic nonselective RAR ligands are capable of <clueType>inducing</clueType> LAP as much as AM580, whereas RAR beta- or RAR gamma-specific ligands are totally <clueType>ineffective</clueType>.</clue>
</event>
<event assertion="non-exist" id="E30">
<type class="Positive_regulation" />
<theme idref="T42" />
<cause idref="T45" />
<clue><clueLoc>In NB4 cells</clueLoc>, two other synthetic nonselective RAR ligands are capable of <clueType>inducing</clueType> LAP as much as AM580, whereas RAR beta- or RAR gamma-specific ligands are totally <clueType>ineffective</clueType>.</clue>
</event>
<sentence id="S8">These results show that <term sem="Organic_compound_other" id="T46" lex="AM580">AM580</term> is more powerful than <term sem="Organic_compound_other" id="T47" lex="ATRA">ATRA</term> in modulating the expression of <term sem="Protein_family_or_group" id="A11">differentiation antigens</term> only in cells in which <term sem="Protein_molecule" id="T48" lex="PML-RAR">PML-RAR</term> is present.</sentence>
<event id="E31">
<type class="Gene_expression" />
<theme idref="A11" />
<clue>These results show that AM580 is more powerful than ATRA in modulating the <clueType>expression</clueType> <linkTheme>of</linkTheme> differentiation antigens only in cells in which PML-RAR is present.</clue>
</event>
<event id="E32">
<type class="Regulation" />
<theme idref="E31" />
<cause idref="T46" />
<clue>These results show that AM580 is more powerful than ATRA in <clueType>modulating</clueType> the expression of differentiation antigens only in cells in which PML-RAR is present.</clue>
</event>
<event id="E33">
<type class="Regulation" />
<theme idref="E31" />
<cause idref="T47" />
<clue>These results show that AM580 is more powerful than ATRA in <clueType>modulating</clueType> the expression of differentiation antigens only in cells in which PML-RAR is present.</clue>
</event>
<event id="E53">
<type class="Regulation" />
<theme idref="E32" />
<cause idref="T46" />
<clue>These results show that AM580 is <clueType>more powerful</clueType> than ATRA in modulating the expression of differentiation antigens <clueLoc>only in cells in which PML-RAR is present.</clueLoc></clue>
</event>
<event id="E34">
<type class="Gene_expression" />
<theme idref="T48" />
<clue>These results show that AM580 is more powerful than ATRA in modulating the expression of differentiation antigens only in cells in which PML-RAR is <clueType>present</clueType>.</clue>
</event>
<sentence id="S9">Binding experiments, using <term sem="Cell_cultured" id="T49" lex="COS-7_cell">COS-7 cells</term> transiently transfected with <term sem="Protein_molecule" id="T50" lex="PML-RAR">PML-RAR</term> and the normal <term sem="Protein_molecule" id="T51" lex="RAR_alpha">RAR alpha</term>, show that <term sem="Organic_compound_other" id="T52" lex="AM580">AM580</term> has a lower affinity than <term sem="Organic_compound_other" id="T53" lex="ATRA">ATRA</term> for both receptors.</sentence>
<event id="E35">
<type class="Binding" />
<theme idref="T52" />
<theme idref="T50" />
<clue><clueExperiment>Binding experiments, using COS-7 cells transiently transfected with PML-RAR and the normal RAR alpha</clueExperiment>, show that AM580 <clueType>has</clueType> a lower <clueType>affinity</clueType> than ATRA <linkTheme>for</linkTheme> <corefTheme idref1="T50">both receptors</corefTheme>.</clue>
</event>
<event id="E36">
<type class="Binding" />
<theme idref="T52" />
<theme idref="T51" />
<clue><clueExperiment>Binding experiments, using COS-7 cells transiently transfected with PML-RAR and the normal RAR alpha</clueExperiment>, show that AM580 <clueType>has</clueType> a lower <clueType>affinity</clueType> than ATRA <linkTheme>for</linkTheme> <corefTheme idref1="T51">both receptors</corefTheme>.</clue>
</event>
<event id="E37">
<type class="Binding" />
<theme idref="T53" />
<theme idref="T50" />
<clue><clueExperiment>Binding experiments, using COS-7 cells transiently transfected with PML-RAR and the normal RAR alpha</clueExperiment>, show that AM580 <clueType>has</clueType> a lower <clueType>affinity</clueType> than ATRA <linkTheme>for</linkTheme> <corefTheme idref1="T50">both receptors</corefTheme>.</clue>
</event>
<event id="E38">
<type class="Binding" />
<theme idref="T53" />
<theme idref="T51" />
<clue><clueExperiment>Binding experiments, using COS-7 cells transiently transfected with PML-RAR and the normal RAR alpha</clueExperiment>, show that AM580 <clueType>has</clueType> a lower <clueType>affinity</clueType> than ATRA <linkTheme>for</linkTheme> <corefTheme idref1="T51">both receptors</corefTheme>.</clue>
</event>
<sentence id="S10">However, in the presence of <term sem="Protein_molecule" id="T54" lex="PML-RAR">PML-RAR</term>, the <term sem="Organic_compound_other" id="T55" lex="synthetic_retinoid">synthetic retinoid</term> is a much better transactivator of <term sem="DNA_domain_or_region" id="T56" lex="retinoic_acid-responsive_element-containing_promoter"><term sem="Organic_compound_other" id="T57" lex="retinoic_acid">retinoic acid</term>-responsive element-containing promoters</term> than the <term sem="Organic_compound_other" id="T58" lex="natural_retinoid">natural retinoid</term>, whereas, in the presence of <term sem="Protein_molecule" id="T59" lex="RAR_alpha">RAR alpha</term>, <term sem="Organic_compound_other" id="T60" lex="AM580">AM580</term> and <term sem="Organic_compound_other" id="T61" lex="ATRA">ATRA</term> have similar activity.</sentence>
<event id="E41">
<type class="Positive_regulation" />
<theme idref="T56" />
<cause idref="T55" />
<clue>However, in the presence of PML-RAR, the synthetic retinoid is a much better <clueType>transactivator</clueType> <linkTheme>of</linkTheme> retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, in the presence of RAR alpha, AM580 and ATRA have similar activity.</clue>
</event>
<event id="E42">
<type class="Positive_regulation" />
<theme idref="T56" />
<cause idref="T58" />
<clue>However, in the presence of PML-RAR, the synthetic retinoid is a much better <clueType>transactivator</clueType> <linkTheme>of</linkTheme> retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, in the presence of RAR alpha, AM580 and ATRA have similar activity.</clue>
</event>
<event id="E43">
<type class="Positive_regulation" />
<theme idref="E41" />
<cause idref="T54" />
<clue>However, <linkCause>in the presence of</linkCause> PML-RAR, the synthetic retinoid is a <clueType>much better</clueType> transactivator of retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, in the presence of RAR alpha, AM580 and ATRA have similar activity.</clue>
</event>
<event id="E44">
<type class="Positive_regulation" />
<theme idref="T56" />
<cause idref="T60" />
<clue>However, in the presence of PML-RAR, the synthetic retinoid is a much better <clueType>transactivator</clueType> <linkTheme>of</linkTheme> retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, in the presence of RAR alpha, AM580 and ATRA have similar activity.</clue>
</event>
<event id="E45">
<type class="Positive_regulation" />
<theme idref="T56" />
<cause idref="T61" />
<clue>However, in the presence of PML-RAR, the synthetic retinoid is a much better <clueType>transactivator</clueType> <linkTheme>of</linkTheme> retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, in the presence of RAR alpha, AM580 and ATRA have similar activity.</clue>
</event>
<event id="E46">
<type class="Positive_regulation" />
<theme idref="T56" />
<cause idref="T59" />
<cause idref="T60" />
<clue>However, in the presence of PML-RAR, the synthetic retinoid is a much better transactivator of retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, <linkCause>in the presence of</linkCause> RAR alpha, AM580 and ATRA have <clueType>similar activity</clueType>.</clue>
<comment>CAUTION: CLUETYPE IN E44</comment>
</event>
<event id="E146">
<type class="Positive_regulation" />
<theme idref="T56" />
<cause idref="T59" />
<cause idref="T61" />
<clue>However, in the presence of PML-RAR, the synthetic retinoid is a much better transactivator of retinoic acid-responsive element-containing promoters than the natural retinoid, whereas, <linkCause>in the presence of</linkCause> RAR alpha, AM580 and ATRA have <clueType>similar activity</clueType>.</clue>
<comment>CAUTION: CLUETYPE IN E44</comment>
</event>
<sentence id="S11">This may explain the strong <term sem="Other" id="T62" lex="cyto-differentiating_potential">cyto-differentiating potential</term> of <term sem="Organic_compound_other" id="T63" lex="AM580">AM580</term> in <term sem="Cell_natural" id="T64" lex="PML-RAR-containing_leukemic_cell"><term sem="Protein_molecule" id="T65" lex="PML-RAR">PML-RAR</term>-containing leukemic cells</term>.</sentence>
<event id="E47">
<type class="Gene_expression" />
<theme idref="T65" />
<clue>This may explain the strong cyto-differentiating potential of AM580 in PML-RAR-<clueType>containing</clueType> <clueLoc>leukemic cells</clueLoc>.</clue>
</event>
<event id="E48">
<type class="Cell_differentiation" />
<theme idref="T64" />
<clue>This may explain the strong <clueType>cyto-differentiating</clueType> potential of AM580 in PML-RAR-containing leukemic cells.</clue>
</event>
<event id="E148">
<type class="Positive_regulation" />
<theme idref="E48" />
<cause idref="T63" />
<clue>This may explain the strong cyto-differentiating <clueType>potential</clueType> <linkCause>of</linkCause> AM580 in PML-RAR-containing leukemic cells.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
